CompoAtlas

40+ Heart Defense

Withdrawn from the US market on 7 November 2023 (according to the DSLD)

Life, food supplement from the US market

Label withdrawn from the US market. 40+ Heart Defense (Life), a food supplement au code-barres 860721000402, is described by its US market label. If sold in France, it would be subject to 2 points of French or European regulation, detailed below. Doses of niacine are not compared: their US units depend on the form. The formula sold in Europe under the same name may differ.

Official label. Dietary Supplement Label Database (DSLD), US National Institutes of Health: current and off-market labels, retrieved 27 October 2026.

Source: NIH Office of Dietary Supplements, Dietary Supplement Label Database (CC0); US market labels.

If this product were sold in France

A daily dose is calculated only if the label gives the maximum number of servings and a unit of mass (or international units for vitamin D). Quantities come from the label, not an analysis. In the United States, the label presents this product as a ‘dietary supplement’; in France, a product of this type may belong to another category (a sports powder, for example), and maximum food supplement doses do not apply to it.

Label composition

Brand
Life
Barcode
860721000402
Form
Capsule
One serving
1 capsule
Servings
up to 1 serving per day
Other ingredients (in English, as written)
Stearic Acid, Calcium Carbonate, Magnesium Stearate, Gelatin, FD&C Yellow #5, FD&C Yellow #6, FD & C Blue #1, FD & C Red #40, Titanium Dioxide
Ingredient (as written, in English)CategoryPer serving
Vitamin CVitamin700 mg
Moringa oleifera (leaf) powder (Moringa oleifera)Plant25 mg
Bryophyllum pinnatumPlant25 mg
Essential Amino Acids:
ArginineAmino acid0.214 mg
HistidineAmino acid0.064 mg
IsoleucineAmino acid0.524 mg
LeucineAmino acid1.676 mg
LysineAmino acidnot stated
MethionineAmino acid0.407 mg
PhenylalanineAmino acid0.56 mg
ThreonineAmino acid0.272 mg
TryptophanAmino acidnot stated
ValineAmino acid1.209 mg
Vitamins & MineralsBlendnot stated
CaroteneOther substance7.84 µg
ThiamineVitaminnot stated
RiboflavinVitamin6.89 µg
NiacinVitamin2.42 µg
OtherBlendnot stated
FiberFibre243.28 mg
CaloriesOther0.404 Calorie(s)
AlkaloidsOther substance0.56 mg
SaponinsOther substance183.036 mg
TanninsOther substance90.96 mg
FlavonoidsOther substance120.23 mg
Minerals:
MagnesiumMineral914.24 µg
CalciumMineral8.64 mg
PotassiumMineral625.709 µg
PhosphorusMineral122.103 mg
SodiumMineral180.791 µg
IronMineral54.323 mg
ZincMineral1.474 µg
ManganeseMineral1.393 µg
CopperMineral0.425 µg
MacronutrientsBlendnot stated
CarbohydratesCarbohydrate44.81 mg
ProteinsBlend114.04 mg
LipidsFat44.87 mg
SugarCarbohydratenot stated
LactoseCarbohydratenot stated
SucroseCarbohydrate0.58 mg
GlucoseCarbohydrate0.3 mg
FructoseCarbohydrate0.17 mg
MaltoseCarbohydrate0.263 mg

Displayed label: Official label. Labels on the market are prioritised, followed by the most recent for the same status.

This information reproduces the US label recorded by the US National Institutes of Health (NIH). It does not say whether the product is effective and does not replace advice from a doctor or pharmacist, particularly during pregnancy or when taking medication.

Official warnings (Health Canada)

Health Canada publishes warnings on these ingredients:

  • Arginine
    Read the warning, when it applies and the studies cited

    L-ARGININE

    Route of administration: Oral

    Cautions and warnings

    Condition of application: All products.

    Ask a health care practitioner/health care provider/health care professional/doctor/ physician before use if you are pregnant or breastfeeding.

    Condition of application: Improvement in exercise capacity in individuals with stable CVD.

    Ask a health care practitioner/health care provider/health care professional/doctor/ physician if your symptoms worsen.

    Applies to products providing more than 0.42 g of L-Arginine, per day.

    Ask a health care practitioner/health care provider/health care professional/doctor/ physician before use if you have a cardiovascular disease and are attempting an increase in physical activity (Doutreleau et al. 2010; Doutreleau et al. 2006; Schulman et al. 2006; Goldman and Ausiello 2004; Nagaya et al. 2001; Bednarz et al. 2000; Ceremużyński et al. 1997; Rector et al. 1996).

    Sources cited by Health Canada (7)
    • Bednarz B, Wolk R, Chamiec T, Herbaczyńska-Cedro K, Winek D, Ceremużyński L. Effects of oral L-arginine supplementation on exercise-induced QT dispersion and exercise tolerance in stable angina pectoris. International Journal of Cardiology 2000;75(2-3):205-210. PubMed Randomised trial
    • Ceremużyński L, Chamiec T, Herbaczyńska-Cedro K. Effect of supplemental oral L-arginine on exercise capacity in patients with stable angina pectoris. The American Journal of Cardiology 1997;80(3):331-333. PubMed Randomised trial
    • Doutreleau S, Rouyer O, Di Marco P, Lonsdorfer E, Richard R, Piquard F, Geny B. L-Arginine supplementation improves exercise capacity after a heart transplant. American Journal of Clinical Nutrition. 2010. Doi: 10.3945/ajcn.2009.27881. DOI
    • Doutreleau S, Mettauer B, Piquard F, Rouyer O, Schaefer A, Lonsdorfer J., Beny B. Chronic L-Arginine Supplementation Enhances Endurance Exercise Tolerance in Heart Failure Patients. International Journal of Sports Medicine 2006;27(7):567-572. PubMed
    • Nagaya N, Uematsu M, Oya H, Sato N, Sakamaki F, Kyotani S, Ueno K, Nakanishi N, Yamagishi M, Miyatake K. Short-term oral administration of L-arginine improves hemodynamics and exercise capacity in patients with precapillary pulmonary hypertension. American Journal of Respiratory and Critical Care Medicine 2001;163(4):887-891. PubMed Randomised trial
    • Rector TS, Bank AJ, Mullen KA, Tschumperlin LK, Sih R, Pillai K, Kubo SH. Randomized, double-blind, placebo-controlled study of supplemental oral –arginine in patients with heart failure. Circulation 1996;93(12):2135-2141. PubMed Randomised trial
    • Schulman SP, Becker LC, Kass DA, Champion HC, Terrin ML, Forman S, Ernst KV, Kelemen MD, Townsend SN, Capriotti A, Hare JM, Gerstenblith G. L-Arginine therapy in acute myocardial infarction: the vascular interaction with age in myocardial infarction (VINTAGE MI) randomised clinical trial. Journal of American Medical Association 2006;295(1):58-64. PubMed Randomised trial

    1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).

    Ask a health care practitioner/health care provider/health care professional/doctor/ physician before use if you are taking medication for cardiovascular diseases, erectile dysfunction, and/or blood thinners (Huynh et al. 2002; Parker et al. 2002; Siani et al. 2000; Adams et al. 1995).

    Sources cited by Health Canada (4)
    • Adams MR, Forsyth CJ, Jessup W, Robinson J, Celermajer DS. Oral L-arginine inhibits platelet aggregation but does not enhance endothelium-dependent dilation in healthy young men. Journal of the American College of Cardiology 1995;26(4):1054-1061. PubMed Randomised trial
    • Huynh NT, Tayek JA. Oral arginine reduces systemic blood pressure in type 2 diabetes: Its potential role in nitric oxide generation. American College of Nutrition 2002;21(5):422-427. PubMed Clinical trial
    • Parker JO, Parker JD, Caldwell RW, Farrell B, Kaesemeyer WH. The effect of supplemental L-arginine on tolerance development during continuous transdermal nitroglycerin therapy. Journal of the American College of Cardiology 2002;39(7):1199-1203. PubMed Randomised trial
    • Siani A, Pagano E, Iacone R, Iacoviello L, Scopacasa F, Strazzullo P. Blood pressure and metabolic changes during dietary L-arginine supplementation in humans. American Journal of Hypertension 2000;13(5):547-551. PubMed Randomised trial

    Contraindications

    Applies to products providing more than 9 g of L-Arginine, per day.

    Do not use if you have had a heart attack/myocardial infarction (Sun et al. 2009; Schulman et al. 2006; Bednarz et al. 2005).

    Sources cited by Health Canada (3)
    • Bednarz B, Jaxa-Chamiec T, Maciejewski P, Szpajer M, Janik K, Gniot J, Kawka-Urbanek T, Drozdowska D, Gessek J, Laskowski H. Efficacy and safety of oral L-arginine in acute myocardial infarction. Results of the multicenter, randomized, double-blind, placebo-controlled ARAMI pilot trial. Kardiol Pol. 2005;62(5):421-427. PubMed Randomised trial
    • Schulman SP, Becker LC, Kass DA, Champion HC, Terrin ML, Forman S, Ernst KV, Kelemen MD, Townsend SN, Capriotti A, Hare JM, Gerstenblith G. L-Arginine therapy in acute myocardial infarction: the vascular interaction with age in myocardial infarction (VINTAGE MI) randomised clinical trial. Journal of American Medical Association 2006;295(1):58-64. PubMed Randomised trial
    • Sun T, Zhou WB, Luo XP, Tang YL, Shi HM. Oral L-arginine supplementation in acute myocardial infarction therapy: a meta-analysis of randomized controlled trials. Clin Cardiol. 2009;32(11):649-652. PubMed Meta-analysis

    Known adverse reactions

    Applies to products providing more than 9 g of L-Arginine, per day.

    When using this product you may experience gastrointestinal discomfort/disturbances (Grimble 2007; Evans et al. 2004; IOM 2005; Clarkson et al. 1996).

    Sources cited by Health Canada (4)
    • Clarkson P, Adams MR, Powe AJ, Donald AE, McCredie R, Robinson J, McCarthy SN, Keech A, Celermajer DS, Deanfield JE. Oral L-arginine endothelium-dependent dilation in hypercholesterolemic young adults. Journal of Clinical Investigation 1996;97(8):1989-1994. PubMed Randomised trial
    • Evans WR, Fernstrom JD, Thompson J, Morris SM Jr, Kuller LH. Biochemical responses of healthy subjects during dietary supplementation with L-arginine. Journal of Nutritional Biochemistry 2004;15(9):534-539. PubMed
    • Grimble GK. Adverse gastrointestinal effects of arginine and related amino acids. The Journal of Nutrition 2007;137(6 Suppl 2):1693S-1701S. PubMed Review article
    • IOM 2005: Institute of Medicine. Panel on Dietary Reference Intakes for Electrolytes and Water, and the Standing Committee on the Scientific Evaluation of Dietary Reference Intakes, Food and Nutrition Board, Institute of Medicine. Dietary Reference Intakes for Water, Potassium, Sodium, Chloride, and Sulfate. Washington (DC): National Academies Press; 2005.

    Health Canada monograph dated 25 July 2025

  • Lysine
    Read the warning, when it applies and the studies cited

    LYSINE

    Route of administration: Oral

    Cautions and warnings

    Applies to products providing more than 300 mg of lysine, per day.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding (Goldman and Ausiello 2004).

    Sources cited by Health Canada (1)
    • Goldman L, Ausiello D, editors. Cecil Textbook of Medicine, Volume 1, 22nd edition. Philadelphia (PA): Saunders; 2004.

    Health Canada monograph dated 19 December 2025

They concern the ingredient, not this product or its dose. They do not replace medical advice.

List declared on (register: Dietary Supplement Label Database (DSLD), US National Institutes of Health: current and off-market labels).

Photograph the packaging

Brand : Life

Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.

Cite this page: CompoAtlas, “40+ Heart Defense : étiquette retirée du marché américain (Life): composition and French regulation”, https://compoatlas.com/en/supplements/us-labels/860721000402-40-heart-defense-life, updated 7 November 2023.

List recorded in 2017. Photograph the packaging to check whether it has changed.

Enter to analyse, Shift+Enter for a new line